| Literature DB >> 33029106 |
Xingxing Tang1, Yudong Cao1, Jia Liu1, Shuo Wang1, Yong Yang1, Peng Du1.
Abstract
BACKGROUND: Inflammation and tumorigenesis are related. We conducted this study to evaluate whether inflammatory factors (IFs) have a diagnostic value for pathology and a predictive value for survival and recurrence in bladder cancer patients undergoing total cystectomy.Entities:
Mesh:
Year: 2020 PMID: 33029106 PMCID: PMC7532356 DOI: 10.1155/2020/9234067
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Patients' characteristics.
| Characteristics | Total |
|---|---|
| Patients ( | 79 |
| Age (year) ( | 63.62 ± 7.52 |
| Sex ( | |
| Male | 70 (88.61) |
| Female | 9 (11.39) |
| Smoking history ( | |
| Yes | 43 (54.43) |
| No | 36 (45.57) |
| BMI ( | 25.63 ± 4.00 |
| Maximum tumor diameter (cm) ( | 3.80 ± 2.17 |
| Grade ( | |
| Low grade | 4 (5.06) |
| High grade | 75 (94.94) |
| Tumor staging ( | |
| Ta | 5 (6.33) |
| T1 | 18 (22.78) |
| T2 | 27 (34.18) |
| T3 | 26 (32.91) |
| T4 | 3 (3.80) |
| N0 | 60 (75.95) |
| N1 | 12 (15.19) |
| N2 | 7 (8.86) |
| M0 | 75 (94.94) |
| M1 | 4 (5.06) |
| Leukocyte count (×109/L) ( | 6.54 ± 1.92 |
| Neutrophil count (×109/L) ( | 4.40 ± 1.72 |
| Lymphocyte count (×109/L) ( | 1.56 ± 0.60 |
| Platelet count (×109/L) ( | 232.95 ± 70.52 |
| Monocyte count (×109/L) ( | 0.41 ± 0.15 |
| NLR ( | 3.22 ± 2.08 |
| dNLR ( | 2.22 ± 1.11 |
| PLR ( | 168.97 ± 80.33 |
| LMR ( | 4.05 ± 1.50 |
| SII ( | 740.38 ± 488.08 |
NLR: neutrophil to lymphocyte ratio; dNLR: derived neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; LMR: lymphocyte to monocyte ratio; SII: systemic immune-inflammation index; BMI: body mass index.
The AUC and cut-off values of the IFs for pathology.
| AUC | SE | 95% CI |
|
| Cut-off value | Sensitivity | Specificity | ||
|---|---|---|---|---|---|---|---|---|---|
| LL | UL | ||||||||
| Grade | |||||||||
| NLR | 0.523 | 0.145 | 0.408 | 0.637 | 0.160 | 0.873 | 2.71 | 50.67 | 25.00 |
| dNLR | 0.577 | 0.142 | 0.460 | 0.687 | 0.539 | 0.590 | 2.45 | 32.00 | 100.00 |
| PLR | 0.703 | 0.186 | 0.590 | 0.801 | 1.094 | 0.274 | 181.37 | 69.33 | 75.00 |
| LMR | 0.683 | 0.122 | 0.569 | 0.783 | 1.504 | 0.133 | 4.18 | 46.67 | 100.00 |
| SII | 0.547 | 0.135 | 0.431 | 0.659 | 0.347 | 0.729 | 650.98 | 60.00 | 75.00 |
| T stage | |||||||||
| NLR | 0.567 | 0.122 | 0.346 | 0.769 | 0.548 | 0.584 | 1.80 | 38.89 | 100.00 |
| dNLR | 0.511 | 0.135 | 0.297 | 0.723 | 0.082 | 0.935 | 2.45 | 66.67 | 0.00 |
| PLR | 0.667 | 0.138 | 0.442 | 0.847 | 1.208 | 0.227 | 172.82 | 77.78 | 60.00 |
| LMR | 0.644 | 0.113 | 0.420 | 0.830 | 1.282 | 0.200 | 4.63 | 50.00 | 100.00 |
| SII | 0.611 | 0.119 | 0.388 | 0.805 | 0.934 | 0.351 | 385.81 | 38.89 | 100.00 |
| Lymph node metastasis | |||||||||
| NLR | 0.706 | 0.083 | 0.586 | 0.807 | 2.464 | 0.014 | 3.12 | 75.00 | 70.00 |
| dNLR | 0.700 | 0.082 | 0.581 | 0.802 | 2.433 | 0.015 | 2.49 | 66.67 | 76.67 |
| PLR | 0.635 | 0.078 | 0.513 | 0.745 | 1.729 | 0.084 | 132.35 | 75.00 | 51.67 |
| LMR | 0.600 | 0.095 | 0.478 | 0.714 | 1.055 | 0.292 | 3.12 | 50.00 | 75.00 |
| SII | 0.704 | 0.071 | 0.585 | 0.806 | 2.890 | 0.004 | 463.56 | 100.00 | 40.00 |
| Systemic metastasis | |||||||||
| NLR | 0.625 | 0.094 | 0.509 | 0.731 | 1.335 | 0.182 | 3.00 | 100.00 | 41.33 |
| dNLR | 0.653 | 0.093 | 0.538 | 0.757 | 1.647 | 0.100 | 2.10 | 100.00 | 46.67 |
| PLR | 0.567 | 0.183 | 0.450 | 0.678 | 0.364 | 0.716 | 118.38 | 75.00 | 65.33 |
| LMR | 0.567 | 0.165 | 0.450 | 0.678 | 0.403 | 0.687 | 2.89 | 100.00 | 26.67 |
| SII | 0.547 | 0.152 | 0.431 | 0.659 | 0.307 | 0.759 | 511.91 | 75.00 | 60.00 |
NLR: neutrophil to lymphocyte ratio; dNLR: derived neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; LMR: lymphocyte to monocyte ratio; SII: systemic immune-inflammation index; AUC: area under curve; 95% CI: 95% confidence interval; SE: standard error; IFs: inflammatory factors; LL: lower limit; UL: upper limit.
Figure 1The receiver operating characteristic curves of NLR, dNLR, and SII for lymph node metastasis. (a) NLR had an acceptable diagnostic value for lymph node metastasis when the cut-off value was 3.12 (AUC = 0.706, sensitivity = 75.00%, specificity = 70.00%, P = 0.014). (b) dNLR had an acceptable diagnostic value for lymph node metastasis when the cut-off value was 2.49 (AUC = 0.700, sensitivity = 66.67%, specificity = 76.67%, P = 0.015). (c) SII had an acceptable diagnostic value for lymph node metastasis when the cut-off value was 463.56 (AUC = 0.704, sensitivity = 100.00%, specificity = 40.00%, P = 0.004).
The association between pathological stage and grade.
| Muscle invasion | Chi-square value |
| ||
|---|---|---|---|---|
| No | Yes | |||
| Grade ( | 10.259 | 0.001 | ||
| Low grade | 4 (100.00) | 0 (0) | ||
| High grade | 19 (25.33) | 56 (74.67) | ||
| Lymph node metastasis ( | 6.896 | 0.009 | ||
| No | 22 (36.67) | 38 (63.33) | ||
| Yes | 1 (5.26) | 18 (94.74) | ||
| Systemic metastasis ( | 1.731 | 0.188 | ||
| No | 23 (30.67) | 52 (69.33) | ||
| Yes | 0 (0.00) | 4 (100.00) | ||
| Maximum tumor diameter ( | 9.168 | 0.002 | ||
| <3 cm | 14 (50) | 14 (50) | ||
| ≥3 cm | 9 (17.65) | 42 (82.35) | ||
The Kaplan-Meier results of OS and RFS grouped by the IFs.
| Cut-off value | Low group | High group |
| |||
|---|---|---|---|---|---|---|
| Events observed | Events expected | Events observed | Events expected | |||
| OS | ||||||
| NLR | 2.00 | 5 | 4.18 | 11 | 11.82 | 0.638 |
| dNLR | 1.80 | 10 | 7.35 | 6 | 8.65 | 0.182 |
| PLR | 133.30 | 10 | 7.13 | 6 | 8.87 | 0.148 |
| LMR | 2.80 | 6 | 3.28 | 10 | 12.72 | 0.090 |
| SII | 547.30 | 10 | 7.74 | 6 | 8.26 | 0.258 |
| RFS | ||||||
| NLR | 3.10 | 12 | 14.52 | 10 | 7.48 | 0.254 |
| dNLR | 1.50 | 5 | 6.92 | 17 | 15.08 | 0.375 |
| PLR | 266.70 | 17 | 19.80 | 5 | 2.20 | 0.044 |
| LMR | 4.70 | 14 | 15.85 | 8 | 6.15 | 0.371 |
| SII | 778.00 | 13 | 15.72 | 9 | 6.28 | 0.195 |
NLR: neutrophil to lymphocyte ratio; dNLR: derived neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; LMR: lymphocyte to monocyte ratio; SII: systemic immune-inflammation index; OS: overall survival; RFS: recurrence-free survival; IFs: inflammatory factors.
Figure 2The Kaplan-Meier curve of RFS grouped by PLR. The low PLR group was significantly better than the high group (P = 0.044) when the cut-off value was 266.70, suggesting PLR has a predictive value for RFS.
The Cox proportional hazards regression of OS and RFS.
| HR | SE | 95% CI |
|
| ||
|---|---|---|---|---|---|---|
| LL | UL | |||||
| OS | ||||||
| NLR | 1.319 | 0.986 | 0.305 | 5.711 | 0.370 | 0.711 |
| dNLR | 0.615 | 0.718 | 0.063 | 6.052 | -0.420 | 0.677 |
| PLR | 0.993 | 0.007 | 0.979 | 1.008 | -0.880 | 0.376 |
| LMR | 1.125 | 0.330 | 0.633 | 1.998 | 0.400 | 0.689 |
| SII | 1.000 | 0.002 | 0.996 | 1.004 | 0.040 | 0.967 |
| Age | 1.098 | 0.037 | 1.028 | 1.172 | 2.780 | 0.005 |
| T stage | 2.144 | 0.931 | 0.915 | 5.023 | 1.760 | 0.079 |
| N stage | 2.238 | 0.967 | 0.960 | 5.217 | 1.860 | 0.062 |
| M stage | 3.815 | 3.314 | 0.695 | 20.942 | 1.540 | 0.123 |
| RFS | ||||||
| NLR | 0.537 | 0.460 | 0.100 | 2.882 | -0.720 | 0.469 |
| dNLR | 1.149 | 1.267 | 0.132 | 9.975 | 0.130 | 0.899 |
| PLR | 1.004 | 0.004 | 0.995 | 1.012 | 0.890 | 0.375 |
| LMR | 1.098 | 0.234 | 0.724 | 1.666 | 0.440 | 0.659 |
| SII | 1.001 | 0.002 | 0.998 | 1.004 | 0.620 | 0.534 |
| T stage | 1.804 | 0.595 | 0.946 | 3.442 | 1.790 | 0.073 |
| N stage | 1.977 | 0.730 | 0.958 | 4.079 | 1.840 | 0.065 |
| M stage | 2.458 | 2.021 | 0.490 | 12.321 | 1.090 | 0.274 |
NLR: neutrophil to lymphocyte ratio; dNLR: derived neutrophil to lymphocyte ratio; PLR: platelet to lymphocyte ratio; LMR: lymphocyte to monocyte ratio; SII: systemic immune-inflammation index; OS: overall survival; RFS: recurrence-free survival; HR: hazard ratio; SE: standard error; 95% CI: 95% confidence interval; LL: lower limit; UL: upper limit.